Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YH002 in advanced solid malignancies
NCT04353102Phase 1Completed
- Sponsor
- Eucure Biopharma
- Start
- Apr 2020
- Primary completion
- Sep 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of YH002 in malignant solid tumor, sponsored by Eucure Biopharma. Primary endpoints: Number of participants with adverse events and serious adverse events up to 2 years, Maximum Tolerated Dose and 1 more. Started Apr 2020; status: completed.
02
Drugs
YH002
03
Conditions
malignant solid tumor
Beyond the preview
Go deeper on NCT04353102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04353102.